US2006275802A1PendingUtilityA1

Mutations in OAS1 genes

61
Individually held — no corporate assignee on recordPriority: May 4, 2005Filed: May 3, 2006Published: Dec 7, 2006
Est. expiryMay 4, 2025(expired)· nominal 20-yr term from priority
Inventors:Shawn P. IadonatoCharles L. MagnessP. Campion FellinChristina SchererTory HagenAmy Olson
C12Q 2600/156A61P 31/16C12N 9/1077A61P 31/04A61K 38/00A61P 35/00C12Q 1/6883C07K 14/00A61P 31/18C12N 9/88A61P 31/14C12N 9/1241A61P 31/12C12N 15/09A61P 31/20A61P 31/22Y02A50/30
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.

Claims

exact text as granted — not AI-modified
1 . (canceled)  
     
     
         2 . An oligoadenylate synthetase 1 protein comprising a polypeptide having the amino acid sequence of SEQ ID NO:1 except for at least one amino acid modification at position 1, 24, 25, 28, 31, 36, 47, 53, 54, 64, 69, 74, 104, 108, 112, 113, 114, 115, 116, 117, 118, 119, 127, 130, 139, 142, 160, 161, 162, 166, 175, 179, 226, 242, 246, 248, 250, 254, 274, 279, 282, 284, 288, 289, 292, 295, 314, 315, and 335.  
     
     
         3 - 5 . (canceled)  
     
     
         6 . An oligoadenylate synthetase 1 protein comprising a polypeptide having the amino acid sequence of SEQ ID NO:2 except for at least one amino acid modification at position 1, 24, 25, 28, 31, 36, 47, 53, 54, 64, 69, 74, 104, 108, 112, 113, 114, 115, 116, 117, 118, 119, 127, 130, 139, 142, 160, 161, 162, 166, 175, 179, 226, 242, 246, 248, 250, 254, 274, 279, 282, 284, 288, 289, 292, 295, 314, 315, 335, 347, 350, 352, 353, 354, 356, 357, 361, 363, 364, 365, 369, 371, 373, 374, 375, 378, 379, 382, 388, 389, and 394.  
     
     
         7 . An oligoadenylate synthetase 1 protein comprising a polypeptide having the amino acid sequence of SEQ ID NO:3 except for at least one amino acid modification at position 1, 24, 25, 28, 31, 36, 47, 53, 54, 64, 69, 74, 104, 108, 112, 113, 114, 115, 116, 117, 118, 119, 127, 130, 139, 142, 160, 161, 162, 166, 175, 179, 226, 242, 246, 248, 250, 254, 274, 279, 282, 284, 288, 289, 292, 295, 314, 315, 335, and 363.  
     
     
         8 . An oligoadenylate synthetase 1 protein comprising a polypeptide having the amino acid sequence of SEQ ID NO:4 except for at least one amino acid modification at position 1, 24, 25, 28, 31, 36, 47, 53, 54, 64, 69, 74, 104, 108, 112, 113, 114, 115, 116, 117, 118, 119, 127, 130, 139, 142, 160, 161, 162, 166, 175, 179, 226, 242, 246, 248, 250, 254, 274, 279, 282, 284, 288, 289, 292, 295, 314, 315, 335, 347, 361, 364, 372, 384, 385, and 399.  
     
     
         9 . An oligoadenylate synthetase 1 protein comprising a polypeptide having the amino acid sequence of any one of SEQ ID NO:5-16.  
     
     
         10 . (canceled)  
     
     
         11 . A therapeutic composition for treating or preventing infection by a virus in a mammal wherein said composition is the polypeptide of any one of claims  2 ,  6 ,  7 ,  8  or  9  together with a pharmaceutically acceptable carrier.  
     
     
         12 . (canceled)  
     
     
         13 . The therapeutic composition of  claim 11  wherein the virus is hepatitis C virus.  
     
     
         14 - 23 . (canceled)  
     
     
         24 . A method for treating a viral disease in a mammalian subject which comprises providing to a subject in need of such treatment a therapeutic composition of  claim 11 .  
     
     
         25 - 28 . (canceled)

Join the waitlist — get patent alerts

Track US2006275802A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.